55 related articles for article (PubMed ID: 32867667)
1. H3K4me1 facilitates promoter-enhancer interactions and gene activation during embryonic stem cell differentiation.
Kubo N; Chen PB; Hu R; Ye Z; Sasaki H; Ren B
Mol Cell; 2024 May; 84(9):1742-1752.e5. PubMed ID: 38513661
[TBL] [Abstract][Full Text] [Related]
2. KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions.
Van HT; Xie G; Dong P; Liu Z; Ge K
J Mol Biol; 2024 Apr; 436(7):168453. PubMed ID: 38266981
[TBL] [Abstract][Full Text] [Related]
3. Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Wang L; Zhao Z; Ozark PA; Fantini D; Marshall SA; Rendleman EJ; Cozzolino KA; Louis N; He X; Morgan MA; Takahashi YH; Collings CK; Smith ER; Ntziachristos P; Savas JN; Zou L; Hashizume R; Meeks JJ; Shilatifard A
Nat Med; 2018 Jun; 24(6):758-769. PubMed ID: 29785026
[TBL] [Abstract][Full Text] [Related]
4. Histone H3K4ac, as a marker of active transcription start sites and enhancers, plays roles in histone eviction and RNA transcription.
Kang J; Kang Y; Kim A
Biochim Biophys Acta Gene Regul Mech; 2024 Jun; 1867(2):195021. PubMed ID: 38417480
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional activity affects the H3K4me3 level and distribution in the coding region.
Okitsu CY; Hsieh JC; Hsieh CL
Mol Cell Biol; 2010 Jun; 30(12):2933-46. PubMed ID: 20404096
[TBL] [Abstract][Full Text] [Related]
6. H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer.
Xiao CK; Ren Y; Chen Q; Yang Y; Tang L; Xu L; Ren Z
Epigenetics; 2024 Dec; 19(1):2343593. PubMed ID: 38643489
[TBL] [Abstract][Full Text] [Related]
7. Clustered PHD domains in KMT2/MLL proteins are attracted by H3K4me3 and H3 acetylation-rich active promoters and enhancers.
Stroynowska-Czerwinska AM; Klimczak M; Pastor M; Kazrani AA; Misztal K; Bochtler M
Cell Mol Life Sci; 2023 Jan; 80(1):23. PubMed ID: 36598580
[TBL] [Abstract][Full Text] [Related]
8. The MLL3/4 complexes and MiDAC co-regulate H4K20ac to control a specific gene expression program.
Wang X; Rosikiewicz W; Sedkov Y; Mondal B; Martinez T; Kallappagoudar S; Tvardovskiy A; Bajpai R; Xu B; Pruett-Miller SM; Schneider R; Herz HM
Life Sci Alliance; 2022 Nov; 5(11):. PubMed ID: 35820704
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic dysregulation and autistic-like behaviors in Kmt2c haploinsufficient mice rescued by an LSD1 inhibitor.
Nakamura T; Yoshihara T; Tanegashima C; Kadota M; Kobayashi Y; Honda K; Ishiwata M; Ueda J; Hara T; Nakanishi M; Takumi T; Itohara S; Kuraku S; Asano M; Kasahara T; Nakajima K; Tsuboi T; Takata A; Kato T
Mol Psychiatry; 2024 Mar; ():. PubMed ID: 38528071
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.
Ma S; Long G; Jiang Z; Zhang Y; Sun L; Pan Y; You Q; Guo X
Eur J Med Chem; 2024 May; 274():116532. PubMed ID: 38805937
[TBL] [Abstract][Full Text] [Related]
11. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
12. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z
Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382
[TBL] [Abstract][Full Text] [Related]
13. KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.
Na F; Pan X; Chen J; Chen X; Wang M; Chi P; You L; Zhang L; Zhong A; Zhao L; Dai S; Zhang M; Wang Y; Wang B; Zheng J; Wang Y; Xu J; Wang J; Wu B; Chen M; Liu H; Xue J; Huang M; Gong Y; Zhu J; Zhou L; Zhang Y; Yu M; Tian P; Fan M; Lu Z; Xue Z; Zhao Y; Yang H; Zhao C; Wang Y; Han J; Yang S; Xie D; Chen L; Zhong Q; Zeng M; Lowe SW; Lu Y; Liu Y; Wei Y; Chen C
Nat Cancer; 2022 Jun; 3(6):753-767. PubMed ID: 35449309
[TBL] [Abstract][Full Text] [Related]
14. KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
Ni C; Wang X; Liu S; Zhang J; Luo Z; Xu B
Sci Rep; 2024 Apr; 14(1):8284. PubMed ID: 38594266
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics and Beyond: Targeting Histone Methylation to Treat Type 2 Diabetes Mellitus.
Yang Y; Luan Y; Feng Q; Chen X; Qin B; Ren KD; Luan Y
Front Pharmacol; 2021; 12():807413. PubMed ID: 35087408
[TBL] [Abstract][Full Text] [Related]
16. Expression Analysis and Mutational Status of Histone Methyltransferase
Laukhtina E; Lemberger U; Bruchbacher A; Ilijazi D; Korn S; Berndl F; D'Andrea D; Susani M; Enikeev D; Compérat E; Shariat SF; Hassler MR
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834500
[TBL] [Abstract][Full Text] [Related]
17. H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma.
Bosgana P; Nikou S; Dimitrakopoulos FI; Logotheti S; Tzelepi V; Kalophonos C; Bravou V; Kourea E; Sampsonas F; Zolota V
Curr Mol Pharmacol; 2021; 14(6):1028-1036. PubMed ID: 32867667
[TBL] [Abstract][Full Text] [Related]
18. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive.
Guccione E; Bassi C; Casadio F; Martinato F; Cesaroni M; Schuchlautz H; Lüscher B; Amati B
Nature; 2007 Oct; 449(7164):933-7. PubMed ID: 17898714
[TBL] [Abstract][Full Text] [Related]
19. Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Chang A; Liu L; Ashby JM; Wu D; Chen Y; O'Neill SS; Huang S; Wang J; Wang G; Cheng D; Tan X; Petty WJ; Pasche BC; Xiang R; Zhang W; Sun P
Cancer Res; 2021 Jun; 81(12):3358-3373. PubMed ID: 33853832
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
